



In Search of Excellence

ORION PHARMA LIMITED

Register Office: Orion House, 153-154 Tejgaon I/A,
Tejgaon, Dhaka-1208

UN-AUDITED THIRD QUARTERLY (Q3) FINANCIAL STATEMENTS

This is for the information of all concerned that the un-audited financial statements of **Orion Pharma Limited** as on and for the 3rd Quarterly period ended March 31, 2017 has been adopted by the Board of Directors in its meeting held on April 30, 2017. The excerpts of the Financial Statements are as follows.

		March 31, 2017		June 30, 2016	
Consolidated NAV per Share - Q3 (Including Revaluation Surplus)	:	BDT. 71.14		BDT. 69.99	
Consolidated NAV per Share - Q3 (Excluding Revaluation Surplus)	:	BDT. 62.63		BDT. 61.34	
		July 01, 2016 to March 31, 2017	July 01, 2015 to March 31, 2016	Jan 01, 2017 to March 31, 2017	Jan 01, 2016 to March 31, 2016
Consolidated Earnings Per Share (EPS)- Q3	:	BDT. 3.02	BDT. 2.33	BDT. 0.56	BDT. 0.33
Consolidated Net Operating Cash Flow Per Share (NOCFPS) - Q3	:	BDT. 8.54	BDT. 10.23	----	----

The Detailed Financial Statements are also available in the Company's website: www.orionpharmabd.com.

Sd/-
Company Secretary

Sd/-
Head of Finance

Sd/-
Director

Dated: Dhaka
April 30, 2017

Sd/-
Managing Director

Sd/-
Chairman